Press Releases

Artielle Immunotherapeutics Initiates Clinical Trials For Multiple Sclerosis

March 14, 2007 — Portland, Ore. — Artielle ImmunoTherapeutics, Inc. today announced that the Company has initiated a Phase I clinical trial to evaluate its novel drug candidate, RTL1000, for the treatment of multiple sclerosis (MS). RTL1000 is a novel protein drug with a highly-selective mechanism of action that targets pathogenic T-cells responsible for triggering and sustaining MS. Full Text

Virogenomics Spin-off, Artielle ImmunoTherapeutics, Secures $11 Million Equity Financing

June 28, 2004 — Portland, Ore. — Virogenomics, Inc. announced today that it has spun-off its autoimmune disease technology into a new company, Artielle ImmunoTherapeutics, Inc. (Artielle), and raised $11 million in venture capital funding for Artielle. Full Text